- Trial expected to start in 1H2019
- Improved protocol may allow for additional claims
Following its meeting with the US Food and Drug Administration (FDA) in Washington DC... read more
Following its meeting with the US Food and Drug Administration (FDA) in Washington DC... read more
Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation... read more
Cellanyx and clinical collaborators today reported results of a prostate cancer clinical study demonstrating the ability of the company’s live tumor cell phenotypic biomarker test to identify... read more
... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,